Loading…
Loading…
See exactly how PPH's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for PPH and 80,000+ other tickers.
VanEck Pharmaceutical ETF (PPH) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.
The Invesco S&P 500 Equal Weight Health Care ETF provides broader exposure with 60 holdings compared to 26 for the VanEck Pharmaceutical ETF. The VanEck Pharmaceutical ETF currently offers a significantly higher dividend yield and a lower expense ratio than its counterpart.
Merck-Moderna's melanoma vaccine success could boost immunotherapy growth, putting healthcare ETFs in the spotlight.
FDA clearance of Lilly and Roche's Alzheimer's blood test highlights a growing diagnostics market and four healthcare ETFs to watch.
VanEck's concentrated 26-stock portfolio has outpaced Fidelity's broader 334-holding fund over five years, but at a steeper cost and higher volatility.
VanEck Pharmaceutical ETF offers a lower-volatility profile and a higher 1.9% dividend yield compared to State Street SPDR S&P Biotech ETF. State Street SPDR S&P Biotech ETF provides broad exposure with 155 holdings, whereas VanEck Pharmaceutical ETF is concentrated in 26 major drugmakers.